Is There a Difference Between a Check Pan Inhibitor and a Diagnostic?

Radiomic signature is that based on the appearance of a tumor on a c t scan, can you learn enough about the features of atumor in its micro environment to predict if it will respond to check pan inhibitor. The payer might play out in such a way that makes the payer the much more incentid party to bring diagnostic to market. But this is an intermediate ground, which isithatwere for for the cases where the diagnostic looks like a companion and requires more wet labside.